Atlas Energy Solutions Inc. AESI 深 沪
已收盘 10-31 16:00:00 美东时间
12.38
+0.310
+2.57%
华盛通- 最 高12.555
- 今 开12.00
- 成交量 337.76万股
- 最 低 11.96
- 昨 收 12.07
- 总市值 15.35亿
- 52周最高 26.11
- 市盈率 静 22.55
- 换手率 2.72%
- 52周最低 10.01
- 委 比 77.78%
- 总股本 1.24亿
- 历史最高 26.11
- 量 比 0.84
- 振 幅 4.93%
- 历史最低 10.01
- 每 手 1
- 风险率 4.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多A Preview Of Atlas Energy Solutions's Earnings
Atlas Energy Solutions (NYSE:AESI) is gearing up to announce its quarterly earn...
11-01 03:01
Atlas Energy Solutions Announces EVP Departure
Atlas Energy Solutions ( ($AESI) ) has shared an update. On October 21, 2025, A...
10-22 00:28
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
Piper Sandler Maintains Neutral on Atlas Energy Solutions, Lowers Price Target to $12
Piper Sandler analyst Derek Podhaizer maintains Atlas Energy Solutions (NYSE:AESI) with a Neutral and lowers the price target from $14 to $12.
10-17 00:36
三叶草生物公布其呼吸道联合疫苗（RSV-hMPV-PIV3）及RSV疫苗重复接种...
❖ 临床数据显示，该呼吸道联合疫苗候选产品（RSV+hMPV±PIV3）极具“同类最佳”潜力，并有望实现对已接种首针RSV疫苗的人群进行有效的重复接种，以重建保...
10-14 19:15
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
RBC Capital Downgrades Atlas Energy Solutions to Sector Perform, Lowers Price Target to $13
RBC Capital analyst Keith Mackey downgrades Atlas Energy Solutions (NYSE:AESI) from Outperform to Sector Perform and lowers the price target from $16 to $13.
10-09 21:44
Kodiak AI Shares Drop Over 6% In Friday Pre-Market: What's Going On?
Kodiak AI, Inc. (NASDAQ: KDK) shares are trending on Friday. Check out the current price of KDK stock here.
09-26 18:15
Roivant And Priovant Report Phase 3 Results For Brepocitinib In Treating Debilitating Skin-Muscle Disease
Roivant (NASDAQ:ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM).On the primary endpoint, brepocitinib 30 mg achieved a week 52
09-17 19:06
